March 13, 2023
Alpine Immune Sciences, Inc. is currently conducting SYNERGY, a phase 2 clinical study to evaluate a novel investigational drug called acazicolcept for the treatment of lupus (NCT04835441). Acazicolcept inhibits two key pathways thought to promote lupus. SYNERGY is being conducted to determine if acazicolcept is safe and potentially helpful for people with moderate or severe lupus who: are 18 to 70 years old began having lupus-related signs or symptoms at least 6 months ago have active lupus despite currently taking medication(s) to treat their disease.
Synergy is currently enrolling participants at study sites in the United States and worldwide. This study will last up to 34 weeks, including a 24-week treatment period. You may be able to continue your current lupus medications while participating in SYNERGY. The study drug will be provided at no cost, and reimbursement is available for study-related expenses such as travel.
For more information please contact email@example.com. We can refer you to one of our study doctors who can tell you more and help determine if you qualify.